Intellia Therapeutics, Inc.
NTLA
$9.06
$0.9611.85%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -101.32M | -101.26M | -114.33M | -128.90M | -135.71M |
| Total Depreciation and Amortization | 4.94M | 2.47M | 2.50M | 2.57M | 2.61M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 15.08M | 19.03M | 21.69M | 39.10M | 38.33M |
| Change in Net Operating Assets | 4.41M | -19.87M | -58.78M | 2.04M | 9.94M |
| Cash from Operations | -76.90M | -99.62M | -148.93M | -85.20M | -84.84M |
| Capital Expenditure | -29.00K | -239.00K | -735.00K | -981.00K | -1.28M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -712.00K | 107.15M | 95.06M | 152.55M | -6.43M |
| Cash from Investing | -741.00K | 106.91M | 94.33M | 151.57M | -7.71M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 114.86M | 14.65M | -- | 2.32M | 82.19M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 114.86M | 14.65M | -- | 2.32M | 82.19M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 37.22M | 21.94M | -54.60M | 68.69M | -10.35M |